BIOAXONE THERAPEUTIC
BioAxone Therapeutic operates as a neuroscience company. The company specializes in the development and commercialization of proprietary technologies that target Rho signaling. It provides an experimental therapy for the treatment of neurological disorders. The company's product includes Cethrin for clinical trial for spinal cord injury. BioAxone Therapeutic was founded in 2000 and is based in Saint-Laurent, Canada.
BIOAXONE THERAPEUTIC
Industry:
Biotechnology Health Care Therapeutics
Founded:
2000-01-01
Address:
Saint-laurent, Manitoba, Canada
Country:
Canada
Website Url:
http://www.bioaxone.com
Total Employee:
11+
Status:
Active
Total Funding:
23.65 M USD
Technology used in webpage:
IPv6 Cloudflare DNS
Similar Organizations
Barrier Therapeutics
Barrier Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization.
Bio Therapeutics, Inc
Bio Therapeutics, Inc is a biopharma company focused on the optimization of protein compounds in order to achieve maximum.
Investors List
Lothian Partners
Lothian Partners investment in Series B - BioAxone Therapeutic
Fonds de solidarité FTQ
Fonds de solidarité FTQ investment in Series B - BioAxone Therapeutic
T2C2 Capital
T2C2 Capital investment in Series B - BioAxone Therapeutic
Desjardins Venture Capital
Desjardins Venture Capital investment in Series B - BioAxone Therapeutic
Official Site Inspections
http://www.bioaxone.com
- Host name: 38.38.90.89
- IP address: 38.38.90.89
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "BioAxone Therapeutic"
BioAxone BioSciences - Crunchbase Company Profile & Funding
Organization. BioAxone BioSciences . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. About. BioAxone is a clinical-stage biopharmaceutical …See details»
BioAxone Therapeutic - Crunchbase Company Profile …
BioAxone Therapeutic operates as a neuroscience company. The company specializes in the development and commercialization of proprietary technologies that target Rho signaling. It provides an experimental therapy for the treatment …See details»
About Us - BioAxone
Jul 5, 2024 BioAxone has developed a novel self-delivering RNA interference compound that reduces expression of PTEN, a protein that blocks axon regeneration in adult neurons. This …See details»
BioAxone Company Profile - Office Locations, Competitors ... - Craft
BioAxone BioSciences is a biopharmaceutical company that develops drugs to treat neurotrauma and neurovascular disorders. Its lead drug candidate is an orally-available inhibitor aimed at …See details»
BioAxone BioSciences | Cambridge, MA, USA Startup - Gust
BioAxone BioSciences Inc. develops proprietary technologies to treat disorders of the central nervous system (CNS). BioAxone’s lead product, Cethrinâ„¢, is disruptive technology in clinical …See details»
BioAxone BioSciences, Inc. - Scientist.com
BioAxone is committed to applying a deep understanding of axon regeneration and neuronal signaling pathways to transform the lives of patients afflicted with neurotrauma or …See details»
BioAxone Company Profile 2024: Valuation, Funding & Investors
BioAxone General Information Description. Operator of a biopharmaceutical company intended to develop drugs to treat neurotrauma and neurovascular disease. The company's drugs aim to …See details»
BioPharmaLink profile of Bioaxone, Canada, Saint-Laurent
BioAxone Therapeutic, a neuroscience company, is developing an experimental therapy for the treatment of neurological disorders. Our lead drug, Cethrin, is in clinical trial for spinal cord …See details»
BioAxone BioSciences - Contacts, Employees, Board Members
BioAxone is a clinical-stage biopharmaceutical company that is transforming treatments for neurotrauma and neurovascular disorders. Search Crunchbase. Start Free Trial . Chrome …See details»
BioAxone Biosciences - VentureRadar
BioAxone is committed to applying a deep understanding of axon regeneration and neuronal signaling pathways to transform the lives of patients afflicted with neurotrauma or …See details»
News | BioAxone
Jun 8, 2021 The workshop was sponsored by the Rick Hansen Institute (RHI), a Canadian-based not-for-profit organization committed to accelerating commercialization of promising …See details»
Transforming treatments for neurotrauma and neurovascular …
BioAxone is a clinical-stage biopharmaceutical company focused on unmet needs in central nervous system disease and ophthalmology. The privately held Massachusetts-based …See details»
Transforming treatments for neurotrauma and neurovascular …
BioAxone is developing a suite of game-changing treatments for spinal cord injury, neurovascular diseases, and eye disorders by targeting Rho/Rho kinase signaling pathways involved in a …See details»
BioAxone Therapeutic - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . May 20, 2005: Series B - …See details»
Clinical Trials - BioAxone
Aug 28, 2020 Jan 9, 2023: Cerebral Cavernous Malformation Drug licensed to Neurelis now a clinical stage drug. Click here for the full story. June 20, 2022: BioAxone BioSciences …See details»
BioAxone BioSciences Announces License of Cerebral Cavernous ...
Jun 21, 2021 BOSTON--(BUSINESS WIRE)--BioAxone BioSciences, Inc., a biotechnology company committed to discovering and developing drugs for unmet needs of neurological …See details»
BioAxone BioSciences | Cambridge MA - Facebook
BioAxone BioSciences, Cambridge, Massachusetts. 97 likes. BioAxone is committed to applying a deep understanding of axon regeneration and neuronal signaling pathways to transform the lives of...See details»
Technology Overview - BioAxone
BioAxone’s scientific team has unmatched knowledge and a deep understanding of Rho signaling pathways, axon regeneration, and neurotrauma. This knowledge and understanding emanates …See details»
Pipeline - BioAxone
Aug 28, 2020 Jan 9, 2023: Cerebral Cavernous Malformation Drug licensed to Neurelis now a clinical stage drug. Click here for the full story. June 20, 2022: BioAxone BioSciences …See details»